Reanalysis of alteplase for stroke stirs controversy
نویسندگان
چکیده
منابع مشابه
Monitoring ovarian cancer: CA125 trial stirs controversy.
M onitoring ovarian cancer with regular blood tests for the CA125 biomarker is a firmly embedded practice in oncology, the theory being that rising CA125 levels may indicate a recurrence, which can be treated effectively upon early detection. But results from a new randomized, controlled trial presented at the annual meeting of the American Association of Clinical Oncology (ASCO) earlier this y...
متن کاملThrombolysis with alteplase after stroke: extending outcomes
1 Ali R, Nicholas RS, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs 2013; published online April 23. DOI:10.1007/s40265-0130030-6. 2 Barkhof F, Simon JH, Fazekas F, et al. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol 2011; 8: 13–21. 3 Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potentia...
متن کاملDRUG PROFILE Alteplase: thrombolysis for acute ischemic stroke
10.1586/14750708.2.5.709 © 2 Alteplase is the only licensed thrombolytic agent for the treatment of acute ischemic stroke. The body of evidence to date suggests that it reduces the number of stroke patients who are dead or dependent at follow up, despite the risk of intracranial hemorrhage. However, in Europe, the license has only been granted for people aged under 80 years who fulfil specific ...
متن کاملRecombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke
THE FOOD AND DRUG ADMINIStration (FDA) approval in June 1996 of intravenous recombinant tissue-type plasminogen activator (rt-PA) for patients with acute ischemic stroke treated within 3 hours of symptom onset marked a historic first step in treating this devastating disease. This approval was primarily based on the results of the National Institute of Neurologic Disorders (NINDS) trials (1 and...
متن کاملThrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study.
BACKGROUND Thrombolysis for acute ischemic stroke has remained controversial. The Canadian Alteplase for Stroke Effectiveness Study, a national prospective cohort study, was conducted to assess the effectiveness of alteplase therapy for ischemic stroke in actual practice. METHODS The study was mandated by the federal government as a condition of licensure of alteplase for the treatment of str...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 2004
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.329.7470.820-f